TriSalus Life Sciences (TLSI) Expected to Announce Quarterly Earnings on Tuesday

Key Points

• TriSalus Life Sciences is set to announce its Q2 2025 earnings on August 12th, with analysts expecting earnings of ($0.22) per share and $10.69 million in revenue.
• In the previous quarter, TriSalus reported earnings of ($0.33) per share, missing estimates, while revenue exceeded expectations at $9.17 million.
• Goldman Sachs recently acquired new shares in TriSalus, buying 33,900 shares, which represents approximately 0.11% ownership of the company.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) is projected to release its Q2 2025 earnings data after the market closes on Tuesday, August 12th. Analysts expect the company to announce earnings of ($0.22) per share and revenue of $10.69 million for the quarter.

TriSalus Life Sciences (NASDAQ:TLSI - Get Free Report) last released its earnings results on Thursday, May 15th. The company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.20) by ($0.13). The company had revenue of $9.17 million for the quarter, compared to analyst estimates of $9.04 million. During the same period in the prior year, the business posted ($0.60) earnings per share. On average, analysts expect TriSalus Life Sciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

TriSalus Life Sciences Price Performance

TriSalus Life Sciences stock traded down $0.02 during midday trading on Tuesday, hitting $4.18. The company's stock had a trading volume of 16,957 shares, compared to its average volume of 57,798. TriSalus Life Sciences has a 1-year low of $3.50 and a 1-year high of $6.04. The company has a 50-day moving average price of $5.04 and a two-hundred day moving average price of $5.28. The company has a market cap of $158.17 million, a price-to-earnings ratio of -3.75 and a beta of 0.48.

Insider Activity

In other news, insider Richard Marshak sold 6,597 shares of the stock in a transaction dated Monday, May 19th. The shares were sold at an average price of $5.18, for a total value of $34,172.46. Following the completion of the sale, the insider owned 69,101 shares in the company, valued at $357,943.18. This represents a 8.71% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In the last 90 days, insiders have sold 16,125 shares of company stock valued at $83,528. 27.50% of the stock is currently owned by insiders.

Hedge Funds Weigh In On TriSalus Life Sciences

A hedge fund recently bought a new stake in TriSalus Life Sciences stock. Goldman Sachs Group Inc. bought a new stake in shares of TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund bought 33,900 shares of the company's stock, valued at approximately $187,000. Goldman Sachs Group Inc. owned approximately 0.11% of TriSalus Life Sciences at the end of the most recent quarter. 2.58% of the stock is owned by hedge funds and other institutional investors.

TriSalus Life Sciences Company Profile

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.